The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index, and 2 are not checked yet.
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
Open accessAbstract
Background/Aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-Ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate AD. An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR. Methods: This double-blind, randomized, placebo-controlled study enrolled 693 subjects. Within 2 APOE allelic strata (Ε4-positive, Ε4-negative), subjects were randomized (2:2:2:1) to once-daily placebo, 2 mg RSG XR, 8 mg RSG XR or 10 mg donepezil (control). Coprimary endpoints were change from baseline to week 24 in the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) score, and week 24 Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC+). Results: At week 24, no significant differences from placebo in change from baseline in coprimary endpoints were detected with either the RSG XR dose in APOE-Ε4-negative subjects or overall. For donepezil, no significant treatment difference was detected in ADAS-Cog; however, a significant difference was detected (p = 0.009) on the CIBIC+. Peripheral edema was the most common adverse event for 8 mg RSG XR (15%) and placebo (5%), and nasopharyngitis for 2 mg RSG XR (7%). Conclusion: No evidence of efficacy of 2 mg or 8 mg RSG XR monotherapy in cognition or global function was detected in the APOE-Ε4-negative or other analysis populations. The safety and tolerability of RSG XR was consistent with its known pharmacology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, phase III clinical trials, using rosiglitazone, failed to show efficacy for the treatment of AD (Gold et al., 2010).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Gold et al., 2010
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 918
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Intranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
Self-citationMeta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders
Profenno, L. A., Porsteinsson, A. P., & Faraone, S. V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.013 · Cited by 718
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Self-citationDe Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657
Schneider, L., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, ., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 646
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 623
Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Fishel, M. A., Kulstad, J. J., Green, P. S., Cook, D. G., et al. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 614
The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1
Burns, A. S., Rossor, M. N., Hecker, J. R., Gauthier, S. G., Petit, H., Möller, H. ‐., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 585
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms
Straus, D. S., & Glass, C. K. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.09.003 · Cited by 563
Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547
Self-citationCraft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487
Self-citationThe Role of Insulin Resistance in the Pathogenesis of Alzheimer??s Disease
Watson, G. S., & Craft, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317010-00003 · Cited by 400
Self-citationIntracerebroventricular insulin enhances memory in a passive-avoidance task
Park, C. R., Seeley, R. J., Craft, S., & WOODS, S. (2000) · Physiology & Behavior · doi:10.1016/s0031-9384(99)00220-6 · Cited by 343
Self-citationFarlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice
Pedersen, W. A., McMillan, P. J., Kulstad, J. J., Leverenz, J. B., Craft, S., & Haynatzki, G. R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.018 · Cited by 320
Self-citationZhang, H., Zhang, A., Kohan, D. E., Nelson, R. D., Gonzalez, F. J., & Yang, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501744102 · Cited by 314
Toledo, E. M., & Inestrosa, N. C. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.72 · Cited by 292
Bauer, B., Hartz, A. M. S., & Miller, D. S. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.029512 · Cited by 275
Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches
Lane, P. (2008) · Pharmaceutical Statistics · doi:10.1002/pst.267 · Cited by 262 · cited 1×
“Donepezil, the most widely used of the ChEI in the treatment of AD, was used as an active control for assay sensitivity in this study. There was no expectation that the effect of donepezil would depend on the APOE e 4 allele status; thus, a smaller number of subjects were enrolled in this group.The full safety populat…”
Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., & Hamel, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3348-08.2008 · Cited by 262
Craft, S., Asthana, S., Cook, D. G., Baker, L. D., Cherrier, M. M., Purganan, K., Wait, C., Petrova, A., Latendresse, S. J., Watson, G. S., et al. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00087-2 · Cited by 254
Self-citationBalfour, J. A. B., & Plosker, G. L. (1999) · Drugs · doi:10.2165/00003495-199957060-00007 · Cited by 198
Craft, S., Dagogo-Jack, S. E., Wiethop, B. V., Murphy, C., Nevins, R. T., Fleischman, S., Rice, V., Newcomer, J. W., & Cryer, P. E. (1993) · Behavioral Neuroscience · doi:10.1037/0735-7044.107.6.926 · Cited by 191
Self-citationRosiglitazone Induces Mitochondrial Biogenesis in Mouse Brain
Strum, J. C., Shehee, R., Virley, D. J., Richardson, J. C., Mattie, M. D., Selley, P., Ghosh, S., Nock, C. M., Saunders, A. M., & Roses, A. D. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11108 · Cited by 183
Self-citationInsulin resistance and hippocampal volume in women at risk for Alzheimer's disease
Rasgon, N., Kenna, H. A., Wroolie, T., Kelley, R. G., Silverman, D. H. S., Brooks, J. O., Williams, K. E., Powers, B. N., Hallmayer, J. F., & Reiss, A. L. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.12.005 · Cited by 180
Frisoni, G. B., Govoni, S., Geroldi, C., Bianchetti, A., Calabresi, L., Franceschini, G., & Trabucchi, M. (1995) · Annals of Neurology · doi:10.1002/ana.410370509 · Cited by 149
Current Alzheimer's disease clinical trials: Methods and placebo outcomes
Schneider, L. S. S., & Sano, M. C. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.07.038 · Cited by 137
Solfrizzi, V., Scafato, E., Capurso, C. A., D’Introno, A., Colacicco, A. M., Frisardi, V., Vendemiale, G., Baldereschi, M., Crepaldi, G., Carlo, A. D., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.12.012 · Cited by 131
Stern, Y., Brandt, J., Albert, M., Jacobs, D. M., Liu, X., Bell, K. L., Marder, K. S., Sano, M. C., Albert, S. M., Castenada, C. D., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410410510 · Cited by 127
Maher‐Edwards, G., Zvartau-Hind, M. E., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383831 · Cited by 117
Self-citationMetabolic Syndrome and Risk of Dementia in Older Adults
Forti, P., Pisacane, N., Rietti, E., Lucicesare, A., Olivelli, V., Mariani, E., Mecocci, P., & Ravaglia, G. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02731.x · Cited by 112
Insulin Resistance in Cognitive Impairment
Geroldi, C., Frisoni, G. B., Paolisso, G., Bandinelli, S., Lamponi, M., Abbatecola, A. M., Zanetti, O. O., Guralnik, J. M., & Ferrucci, L. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1067 · Cited by 112
Long-term effects of rivastigmine in moderately severe Alzheimer's disease
Doraiswamy, P. M., Krishnan, K., Anand, R., Sohn, H., Danyluk, J., Hartman, R. D., & Veach, J. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00326-8 · Cited by 108
Cortes, F., Nourhashémi, F., Guérin, O., Cantet, C., Guyonnet, S., Andrieu, S., Ousset, P., Vellas, B. J., & REAL-FR Group (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.10.018 · Cited by 106
Individual Growth Curve Analysis of APOE ε4–Associated Cognitive Decline in Alzheimer Disease
Hoyt, B. D., Massman, P. J., Schatschneider, C. W., Cooke, N., & Doody, R. S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.3.454 · Cited by 83
Renal and Vascular Mechanisms of Thiazolidinedione‐Induced Fluid Retention
Yang, T., & Soodvilai, S. (2008) · PPAR Research · doi:10.1155/2008/943614 · Cited by 72
Thiazolidinediones and their Fluid-Related Adverse Effects
Karalliedde, J. J., & Buckingham, R. E. (2007) · Drug Safety · doi:10.2165/00002018-200730090-00002 · Cited by 72
Insulin resistance, diabetes and cognitive function: Consequences for preventative strategies
Bourdel‐Marchasson, I., Lapre, É., Laksir, H., & Puget, E. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.03.001 · Cited by 57
Disease Stage in Alzheimer Disease and Treatment Effects of Rivastigmine
Kurz, A., Farlow, M. R., Quarg, P., & Spiegel, R. (2004) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000127445.00442.a1 · Cited by 54
Zhang, H., Zhang, A., Kohan, D. E., Nelson, R. D., Gonzales, F., & Yang, T. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005090935 · Cited by 50
Neuroinflammation Activates Mdr1b Efflux Transport Through NFκB: Promoter Analysis in BBB Endothelia
Yu, C., Argyropoulos, G. A., Zhang, Y., Kastin, A. J., Hsuchou, H., & Pan, W. (2008) · Cellular Physiology and Biochemistry · doi:10.1159/000185558 · Cited by 49
Irizarry, M. C., Webb, D. J., Bains, C., Barrett, S. J., Lai, R. Y. K., Laroche, J. P., Hosford, D. A., Maher‐Edwards, G., & Weil, J. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14304 · Cited by 30
Self-citationGold, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0313 · Cited by 23
Self-citationThe relationship between dysglycemia and cognitive dysfunction.
Cukierman-Yaffee, T. (2009) · PubMed · Cited by 22
Domínguez, R. O., Marschoff, E., Guareschi, E. M., Repetto, M. G., Famulari, A. L., Pagano, M. A., Serra, J. A., & The CGSOSRA – Collaborative Group for the Study of the Oxidative Stress and Related Abnormalities (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0804-7 · Cited by 16
ROSIGLITAZONE IN THE MANAGEMENT OF OLDER PATIENTS WITH TYPE 2 DIABETES MELLITUS
Kreider, M., & Heise, M. A. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11314.x · Cited by 15
Gendelman, H. E. (2007) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9050-2 · Cited by 13
Flagged first, then by citations
Cited by
Sorted by citations
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Self-citationDementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Microglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857
Metadata
- Authors
- Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- Duke University (US)
- University of Washington (US)
- Case Comprehensive Cancer Center (US)
- University of Tartu (EE)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 30
- Issue
- 2
- Pages
- 131-146
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- PMC
- PMC3214882
- OpenAlex
- W1978999542
- Cited by
- 361
- References
- 56
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 20 · 2023: 21 · 2022: 23 · 2021: 25 · 2020: 26 · 2019: 22 · 2018: 22 · 2017: 19 · 2016: 22 · 2015: 24 · 2014: 24 · 2013: 25 · 2012: 31
- FWCI
- 18.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- National Institute on Aging (R01AG030482)
- National Institute of Neurological Disorders and Stroke
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, peroxisome proliferator-activated receptor gamma agonists, APOE ε4 genotype, donepezil, cognitive function, global function, peripheral edema, drug safety and tolerability, ADAS-Cog
- MeSH terms
- Rosiglitazone, Donepezil, Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Cholinesterase Inhibitors, Edema, Female, Genotype, Humans, Hypoglycemic Agents, Indans, Intelligence Tests, Interview, Psychological, Male, Middle Aged, Nasopharyngitis, Piperidines, Treatment Outcome, Thiazolidinediones, PPAR gamma, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
